Professor Ranjit Manchanda

MD, MRCOG, PhD
Consultant Gynaecological Oncologist,
Professor of Gynaecological Oncology
Group Leader, Research Theme Lead
Research Focus

My research interests are focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and approaches for risk prediction, population stratification, targeted screening, cancer prevention and cost-effectiveness analyses.

Key Publications

A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol (2019). PMID: 31580391

Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation-testing in unselected general-population women. J Natl Cancer Inst (2018); 110(7):714-725. PMID: 29361001

Cost effectiveness of population screening for BRCA mutations in Ashkenazi-Jewish women compared to family-history based testing. J Natl Cancer Inst (2015); 107(1):380. PMID: 25435542

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomised controlled trial. J Natl Cancer Inst (2015); 107(1):379. PMID: 25435541

Major Funding
  • 2022-2026 – GSK and North-East London Cancer Alliance, Direct to Patient testing at Cancer diagnosis for Precision Prevention (DETECT). Role- CI, £1.1M
  • 2017-2024 – Barts Charity & Rosetrees Trust, PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal), Role – CI, £548,000
  • 2019-2024- Barts Charity, Barts Cancer Centre Grant: Cancer Prevention & Risk Management Theme. Role- Co-applicant, £1.8M
Other Activities
  • NHS Innovation Accelerator (NIA) Fellow
  • Integrated Academic Training Programme Director, London School of Obstetrics & Gynaecology (LSSOG), Health Education England (HEE)
  • Member National Cancer Programme Early Diagnosis Task & Finish group
  • Topic Advisor/Clinical Lead NICE Guideline on Familial Ovarian Cancer
Research

My research is focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and precision medicine approaches for risk prediction, population stratification, targeted screening, cancer prevention (including surgical prevention) and management of familial gynaecological cancer. I have a keen research interest in health economic issues related to these areas.

I am Chief Investigator (CI) on PROTECT (PROTECT: Population based Germline testing for Early detection and Cancer Prevention); PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial; DETECT-2 (Direct to Patient testing at Cancer diagnosis for Precision Prevention) study; PRESCORES (Prevention of endometrial cancer: Utility scores of risk-reducing strategies); JHCR (Jewish Hereditary Cancer Research); PROMISE Feasibility study (pilot general population testing and personalised ovarian cancer risk prediction study); SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study and RRESDO (study evaluating attitudes towards early salpingectomy) studies; Co-PI of GCaPPS trial (population based BRCA testing RCT in the Jewish population); Co-Lead for UKCOGS (UK COVID and Gynaecological Cancer Study); Co-lead for SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme. I have worked on ovarian cancer screening trials (UKCTOCS, UKFOCSS and ALDO).

Other Activities

Academic Roles (select):

  • Co-Lead Cancer Prevention Unit, Wolfson Institute of Population Health, Queen Mary University of London
  • Co-Lead for Cancer Prevention (Theme-1), CRUK Barts Centre, Queen Mary University of London
  • NHS Innovation Accelerator (NIA) Fellow
  • Integrated Academic Training Programme Director, London School of Obstetrics & Gynaecology (LSSOG), Health Education England (HEE)
  • Lead for the RCOG Advanced Professional Module (APM) in Clinical Research for London
  • Specialty Research Lead for Gynaecological Cancer, National Institute for Health Research (NIHR), North Thames Clinical Research Network (CRN)
  • Honorary Professor, Department of Health Services Research, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine
  • Infosys Chair in Oncology, AIIMS, New Delhi, India

Clinical Roles (select):

  • Lead Women’s Precision Prevention Service, Barts Health NHS Trust
  • Chair London Cancer High Risk Gynaecological Cancer MDT
  • North Thames GLH Clinical Lead for Gynaecological Cancer
  • Member National Cancer Programme Early Diagnosis Task & Finish group
  • Topic Advisor NICE Guideline on Familial Ovarian Cancer
  • Deputy Director Gynae-oncology RCOG training programme

Other roles:

  • Associate Editor Trials; Guest Editor Cancers (Basel): Special Issue Women’s Cancers Risk
  • Member of number of advisory bodies and oversight committees
  • President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011-2013

Clinical Interests: Ovarian cancer radical debulking surgery, Sentinel node biopsy, Management of women at high risk of gynaecological cancer

Major Funding
  • 2022-2026 – GSK and North-East London Cancer Alliance, Direct to Patient testing at Cancer diagnosis for Precision Prevention (DETECT). Role- CI, £1.1M
  • 2017-2024 – Barts Charity & Rosetrees Trust, PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal), Role – CI, £548,000
  • 2019-2024- Barts Charity, Barts Cancer Centre Grant: Cancer Prevention & Risk Management Theme. Role- Co-applicant, £1.8M
  • 2019- NHS Innovation Accelerator Fellowship, £20,000 annual
  • 2020-2022, BGCS, UKCOGS: UK COVID and Gynaecological Cancer Study. Role- Co-Lead, £29,300
  • 2020-2021, CRUK & DBT India, SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management. Co-Lead, £30,000.
  • 2019- 2023, China Medical Board, Value based genetic testing technology - breast cancer in China. Role - Co-Investigator, $75,000
  • 2016-2022- Barts Charity, Systematic genetic testing for ovarian cancer (SIGNPOST). Role- CI, £259,000
  • 2019-2023- Cancer Research UK, Targeting the innate immune system in high grade serous ovarian cancer (Canbuild). Role- Co-investigator, £1.95M
  • 2017-2020- UKIERI, UK India Education Research Initiative, Investigating BRCAness in epithelial ovarian cancer in India to develop stratified surgical & chemotherapy options. Role- Co-investigator, Partner. £194,405
  • 2016–2019- CRUK and The Eve Appeal, PROMISE Feasibility Study Role- CI, £130,000
  • 2016-2019- Cancer Research UK, Developing Core Outcomes Sets to standardise reporting in endometrial cancer & atypical endometrial hyperplasia. Role- Co-investigator, £163,790
  • 2016-2018- The Eve Appeal, Evaluating cost-effectiveness of population testing for ovarian/breast cancer gene mutations in the general population. Role – CI, £77,340
  • 2011-2019- CRUK & The Eve appeal, PROMISE 2016 Programme. Role - Co-investigator, £3M
  • 2008-2019- The Eve Appeal, Genetic Cancer Prediction through population Screening (GCaPPS). Acting CI, £561,523
  • 2010-2014, NIHR, NIHR Walport Academic Clinical Lecturer Award, £261,800
Recent Publications

The DNA methylome of cervical cells can predict the presence of ovarian cancer Barrett JE, Jones A, Evans I et al. Nature Communications (2022) 13(7)

Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews Gaba F, Oxley S, Liu X et al. Diagnostics 12(13) 1028-1028

Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China Sun L, Cui B, Wei X et al. Cancers (2022) 14(7)

British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic Taylor A, Sundar SS, Bowen R et al. Obstetrical & Gynecological Survey (2022) 77(10) 156-157

Post-recurrence survival in patients with cervical cancer Cibula D, Dostálek L, Jarkovsky J et al. Gynecologic Oncology (2022) 164(7) 362-369

Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: A qualitative study Gaba F, Goyal S, Marks D et al. Journal of Medical Genetics (2022) 59(7) 122-132

Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer Manchanda R (2022) (1)

Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS Taylor JA, Burnell M, Ryan A et al. BJOG: An International Journal of Obstetrics and Gynaecology (2022) 129(7) 110-118

British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic Taylor A, Sundar SS, Bowen R et al. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022) 32(7) 9-14

Concise Reporting of Benign Endometrial Biopsies is an Acceptable Alternative to Descriptive Reporting. Kriplani D, Olivar AA, Tchrakian N et al. Int J Gynecol Pathol (2022) 41(2) 20-27
https://www.ncbi.nlm.nih.gov/pubmed/33664191

For additional publications, please click here
Team

Academic Clinical Lecturer

  • Dr Michail Sideris

Senior Research Fellow

  • Li Sun

Clinical Trials Coordinator

  • Nicole Itzkowitz
  • Hannah Nudds

PhD Students

  • Ms Faiza Gaba
  • Ms Dhivya Chandrasekaran
  • Ms Xia Wei
  • Dr Samuel Oxley
  • Ms Jyotsna Pundir

Honorary Research Fellows

  • Ashwin Kalra
  • Monika Sobocan
  • Katrina Sarig
Biography

I was appointed as Professor of Gynaecological Oncology at Wolfson Institute of Population Health, Queen Mary University of London in Sep 2019. I joined Barts Cancer Institute, Queen Mary, as a Clinical Senior Lecturer in June 2015. I have worked as a consultant Gynaecological Oncologist at Barts Health NHS Trust from June 2015. From 2014- 2015 I worked as a Locum Consultant Gynaecological Oncologist at Barts Health and Honorary Senior Lecturer at University College London, UK. I completed a PhD in gynaecological oncology at UCL, followed by a NIHR ACL Fellowship and subspecialty training in gynaecological oncology from UCLH and Bart's Hospital.

I am Co-Lead for Cancer Prevention Unit, Wolfson Institute of Population Health, Queen Mary; and Co-Lead for Cancer Prevention (Theme-1), CRUK Barts Centre. I was awarded an NHS Innovation Accelerator Fellowship in March 2019. I am Chief Investigator (CI) on PROTECT (PROTECT: Population based Germline testing for Early detection and Cancer Prevention); PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial; DETECT-2 (Direct to Patient testing at Cancer diagnosis for Precision Prevention) study; PRESCORES (Prevention of endometrial cancer: Utility scores of risk-reducing strategies); JHCR (Jewish Hereditary Cancer Research); PROMISE Feasibility study (pilot general population testing and personalised ovarian cancer risk prediction study); SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study and RRESDO (study evaluating attitudes towards early salpingectomy) studies; Co-PI of GCaPPS trial (population based BRCA testing RCT in the Jewish population); Co-Lead for UKCOGS (UK COVID and Gynaecological Cancer Study); Co-lead for SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme. I have worked on ovarian cancer screening trials (UKCTOCS, UKFOCSS and ALDO).

I lead the Barts Health Women’s Precision Prevention Service, Chair the London Cancer High Risk Gynaecological Cancer MDT, Member National Cancer Programme Early Diagnosis Task & Finish group, Topic Advisor (Clinical Lead) for the NICE Guideline on Familial Ovarian Cancer, and Clinical Lead for Gynaecological Cancer North Thames GLH. I am scientific advisor to BRCA Umbrella and GO Girls, Chair the Independent Advisory Committee of the Mermaid Project (Demark) and serve on number of oversight committees.

I am actively involved in gynaecological oncology training issues. I helped develop and establish ENYGO (European Network of Young Gynaecological Oncologists) from its inception and have led/undertaken a number of initiatives for European and International trainees in gynaecological oncology. I have served as the president of the European Network of young Gynaecological Oncologists (ENYGO) and a member of the European Society of Gynaecological Oncology (ESGO) council (2011-2013). I am the Integrated Academic Training Programme Director and lead for the RCOG Advanced Professional Module (APM) in Clinical Research for London Specialty School of Obstetrics & Gynaecology, Health Education England. I am the deputy director of the Barts Health RCOG gynaecological oncology training programme and Mentor for the IGCS Gynecologic Oncology Global Curriculum & Mentorship Program.

Previous posts

  • Sep 2021 – Feb 2022 - Director Graduate Studies, Wolfson Institute of Population Health, Queen Mary University of London
  • June 2015- Sep 2019 - Clinical Senior Lecturer, Barts Cancer Institute, Queen Mary University of London
  • March 2014-May 2015 - Consultant Gynaecological Oncologist at Barts Hospital & Honorary Senior Lecturer at University College London
  • Feb 2010-Feb 2014 - NIHR Walport Clinical Lecturer & Sub-Specialty trainee Gynaecological Oncology (University College London Hospital, Bart’s Hospital, University College London)
  • Feb 2007-Jan 2010 - Clinical Research Fellow, Gynaecological Oncology (University College London)
  • Sep 2001-Jan 2007 - Specialist Registrar Obstetrics & Gynaecology East of England Training Programme (Cambridge rotation)
  • July 2000-July 2001 - Indian Council Medical Research Fellowship, Obstetrics & Gynaecology, All India Institute of Medical Sciences, India
  • July 1993-Oct 1999 - Junior and Senior Resident Obstetrics & Gynaecology (6 year training programme), All India Institute of Medical Sciences (AIIMS), India

Education & Qualifications

  • 2014- CCT in Gynaecological Oncology and CCT in Obstetrics & Gynaecology
  • 2014- BSCCP accreditation in Colposcopy: BSCCP
  • 2013- PhD (Gynaecological Oncology): University College London, UK
  • 2011- NIHR Leadership Programme for Trainees: Ashridge Business School, UK
  • 2005- MRCOG : Royal College of Obstetricians & Gynaecologists (RCOG), UK
  • 1996- MD (Obstetrics & Gynaecology): All India Institute of medical Sciences (AIIMS), Delhi, India
  • 1993- M.B.B.S : All India Institute of medical Sciences (AIIMS), Delhi, India